NIKKEI 225
38,967.27 +477.10 (+1.24%) HANG SENG
18,424.96 -19.15 (-0.10%) CRUDE OIL
74.48 +0.41 (+0.55%) GOLD FUTURES
2,374.30 -1.20 (-0.05%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,465.92 +238.93 (+0.43%)
Atossa Therapeutics Inc (YAG2.MU)
| Previous close | 1.2320 |
| Open | 1.2320 |
| Bid | 1.1820 x 0 |
| Ask | 1.2320 x 0 |
| Day's range | 1.2320 - 1.2320 |
| 52-week range | 0.6000 - 2.0600 |
| Volume | |
| Avg. volume | 99 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAtossa to Present at the Sidoti Small-Cap Investor Conference
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unm
- GlobeNewswire
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model i
ZacksAtossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
